Gene 420

Company Overview

Snapshot

Founded in March 2018 by Ophir Nevo, Uri Aizik, Mark Fainstein, and Yoav Orlev, Gene 420 operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing its DNA-based recommendation platform for cannabis users.

Business overview

Gene 420 is a Health Tech & Life Sciences company focused on digital healthcare and medical cannabis. It develops a core technology that provides DNA-based recommendations for cannabis products, aiming to enhance the safety, intelligence, and enjoyment of cannabis consumption. The company serves both medicinal and recreational cannabis users, as well as sellers, by offering a marketplace to match products with customer needs. Gene 420 operates within the personalized medicine, precision medicine, and digital therapeutics sectors, targeting patients and consumers in the cannabis market.

Company Intelligence Q&A

What is Gene 420's primary offering?

Gene 420 offers DNA-based recommendations for cannabis products, combining genetic insights with questionnaire results to personalize cannabis consumption for users.

When was Gene 420 founded and by whom?

Gene 420 was founded in March 2018 by Ophir Nevo, Uri Aizik, Mark Fainstein, and Yoav Orlev.

What markets does Gene 420 currently target?

Gene 420 targets the markets of Israel and the United States with its DNA-based cannabis recommendation platform.

What is the current product stage of Gene 420?

Gene 420's product, Gene420, is currently in its Beta stage of development, as of December 2018.

What is Gene 420's business model?

Gene 420 operates with a B2C (Business-to-Consumer) business model, directly serving individual cannabis users and sellers.